Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AADR vs APVO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

APVO Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–3 Matrix Metrics)

APVO Overall Winner 6-Pillar Tally: AADR 1 – 3 APVO (2 Tie) Matrix Metrics: AADR 3 – 7 APVO

As of Nov 16, 2026, Aptevo Therapeutics Inc (APVO) is the stronger overall head-to-head candidate over AdvisorShares Dorsey Wright (AADR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AADR carries a Unified Composite Score of 57.7/100 (HOLD) at $77.92 (N/M Forward P/E, N/A operating margin), whereas APVO carries 36.9/100 (SELL) at $0.55 (3.9x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AADR currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. APVO 36.9/100 SELL), APVO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-100.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: AADR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile APVO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 10.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AADR vs APVO
AADR NASDAQ
AdvisorShares Dorsey Wright ADR ETF
Institutional Equity
$77.92
-1.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.12β · 23% Vol
Unified Composite Score
57.7 / 100 HOLD
Tech 73.0 Fund 59.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.3%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $79.48 · SMA50: $81.28
APVO NASDAQ Head-to-Head Winner
Aptevo Therapeutics Inc
Pharmaceutical Preparations
$0.55
-7.68% 1D
Market Cap $1.4M
TTM Revenue N/A
Forward P/E 3.9x
Beta / 30D Vol 0.29β · 122% Vol
Unified Composite Score
36.9 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -27.8%), weak momentum, RSI 10
RSI-14: 10.4 · SMA20: $1.23 · SMA50: $1.57

6-Pillar Scorecard Institutional Category Breakdown (AADR 1 – 3 APVO)

Columns: Metric · AADR · APVO
1. Valuation Multiples APVO
Forward P/E N/M 3.9x
Trailing P/E N/M 0.0x
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale APVO
Revenue Growth (YoY) N/A -100.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $1.4M
3. Profitability & Quality APVO
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -420.3%
4. Balance Sheet & Cash Flow AADR
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $4.26 Book/Sh · -420.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AADR (3) vs APVO (7)
Institutional Metric AADR APVO Criterion Row Edge
Market Capitalization
Scale
N/A $1.4M Larger Scale APVO
Trailing P/E Ratio
Valuation
N/M 0.0x Lower Multiple APVO
Forward P/E Ratio
Valuation
N/M 3.9x Lower Multiple APVO
Revenue Growth (YoY)
Growth
N/A -100.0% Higher Growth APVO
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin APVO
Net Profit Margin
Profitability
N/A 0.0% Higher Margin APVO
Return on Equity (ROE)
Capital Efficiency
N/A -420.3% Higher ROE APVO
52-Week Range Position
Momentum
6% ($77–$98) 0% ($0–$11) Stronger Trend AADR
Beta / 30D Volatility
Risk Regime
1.12β · 23% Vol 0.29β · 122% Vol Lower Realized Risk AADR
Unified Institutional Score
Composite Signal
57.7 / 100 (HOLD) 36.9 / 100 (SELL) Higher Composite AADR
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($4.26 Book/Sh · -420.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AADR +63.15 pp
AADR: -2.99% · APVO: -66.14%
3M Horizon AADR +73.75 pp
AADR: -7.34% · APVO: -81.09%
6M Horizon AADR +80.02 pp
AADR: -8.13% · APVO: -88.15%
1Y Horizon AADR +54.29 pp
AADR: -7.88% · APVO: -62.17%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AADR vs APVO. Trailing 12-month operating profitability (AADR N/A vs APVO 0.0%) and valuation multiples (AADR N/M vs APVO 3.9x Forward P/E) are benchmarked directly in Pillar 4 below.

AADR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
APVO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-420.3% · 3.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AADR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AADR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
APVO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact APVO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AADR Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
APVO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AADR vs APVO Key Questions & Quantitative Answers

As of Nov 16, 2026, Aptevo Therapeutics Inc (APVO) is the stronger overall head-to-head candidate over AdvisorShares Dorsey Wright (AADR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). AADR carries a Unified Composite Score of 57.7/100 (HOLD) at $77.92 (N/M Forward P/E, N/A operating margin), whereas APVO carries 36.9/100 (SELL) at $0.55 (3.9x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AADR currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. APVO 36.9/100 SELL), APVO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (-100.0% vs. N/A YoY). Technical & Structure Timing Caution: AADR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9); meanwhile APVO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 10.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

APVO leads the Growth & Scale pillar: AADR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with APVO at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AADR generates N/A in USD-normalized revenue versus N/A for APVO. In operating R&D and SG&A reinvestment, AADR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for APVO.

APVO screens cheaper on headline valuation multiples. AADR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas APVO trades at 3.9x Forward P/E, 0.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AADR (N/A ROE) versus APVO (-420.3% ROE) capital efficiency.

In options market volatility and institutional positioning, AADR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.12β · 23% Vol realized risk). By comparison, APVO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.29β · 122% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.